DRD1 and Parkinson disease: D3R agonists are considered to be effective in the treatment of PD by boosting the dopamine content, reducing α-synuclein accumulation, enhancing brain-derived neurotrophic factor secretion, promoting neurogenesis, and interacting with D1R to reduce the motor symptoms of PD [30].